We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

140 hedge funds and large institutions have $1.19B invested in Protagonist Therapeutics in 2022 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 54 increasing their positions, 47 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

259% more call options, than puts

Call options by funds: $52.9M | Put options by funds: $14.7M

15% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 47

1% more ownership

Funds ownership: 103.59% → 104.59% (+1%)

6% less funds holding

Funds holding: 149 → 140 (-9)

29% less capital invested

Capital invested by funds: $1.67B → $1.19B (-$486M)

31% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 29

50% less funds holding in top 10

Funds holding in top 10: 8 → 4 (-4)

Holders
140
Holders Change
-9
Holders Change %
-6.04%
% of All Funds
2.21%
Holding in Top 10
4
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-50%
% of All Funds
0.06%
New
20
Increased
54
Reduced
47
Closed
29
Calls
$52.9M
Puts
$14.7M
Net Calls
+$38.2M
Net Calls Change
+$11.8M

Top Buyers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
+$61.8M
2
Morgan Stanley
Morgan Stanley
New York
+$34.6M
3
CAC
Cowen and Company
New York
+$20.3M
4
State Street
State Street
Massachusetts
+$19.3M
5
FFM
Fairmount Funds Management
Pennsylvania
+$15.5M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$63.6M
2
DM
Deerfield Management
New York
-$40.1M
3
FCM
Farallon Capital Management
California
-$22.1M
4
SC
Samlyn Capital
New York
-$15.4M
5
MP
Mangrove Partners
Connecticut
-$14.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCAMU
26
Rothschild & Co Asset Management US
Connecticut
$8.98M -$3.15M -111,898 -23%
Goldman Sachs
27
Goldman Sachs
New York
$8.2M +$6.28M +222,730 +180%
CC
28
Commodore Capital
New York
$7.86M -$13.3M -473,687 -59%
Charles Schwab
29
Charles Schwab
California
$7.7M +$228K +8,080 +3%
T. Rowe Price Associates
30
T. Rowe Price Associates
Maryland
$7.12M -$2.16M -76,664 -20%
AAA
31
Affinity Asset Advisors
New York
$7.1M +$1.66M +58,881 +24%
Two Sigma Investments
32
Two Sigma Investments
New York
$6.83M +$7.34M +260,418 +927%
Lord, Abbett & Co
33
Lord, Abbett & Co
New Jersey
$6.53M +$3.16M +112,123 +69%
SC
34
Sessa Capital
New York
$6.09M +$7.24M +257,000 New
OM
35
Opaleye Management
Massachusetts
$5.96M -$2.55M -90,500 -26%
Bank of America
36
Bank of America
North Carolina
$5.87M +$3.61M +128,269 +107%
Two Sigma Advisers
37
Two Sigma Advisers
New York
$5.08M +$4.96M +175,900 +453%
Rafferty Asset Management
38
Rafferty Asset Management
New York
$4.93M +$1.19M +42,322 +26%
Citadel Advisors
39
Citadel Advisors
Florida
$4.42M +$4.26M +151,276 +426%
Russell Investments Group
40
Russell Investments Group
United Kingdom
$4.33M +$550K +19,527 +12%
BFM
41
Boothbay Fund Management
New York
$3.71M +$4.41M +156,641 New
Bank of New York Mellon
42
Bank of New York Mellon
New York
$3.31M +$35.9K +1,275 +0.9%
TLCM
43
Twin Lakes Capital Management
California
$3.3M +$23K +817 +0.6%
Allianz Asset Management
44
Allianz Asset Management
Germany
$3.14M -$58K -2,059 -2%
SEI Investments
45
SEI Investments
Pennsylvania
$3.1M -$44.9K -1,595 -1%
AllianceBernstein
46
AllianceBernstein
Tennessee
$3M +$2.27M +80,563 +176%
UBS Group
47
UBS Group
Switzerland
$2.91M +$1.59M +56,454 +85%
TCM
48
Tekla Capital Management
Massachusetts
$2.9M +$598K +21,234 +21%
SAM
49
Silvercrest Asset Management
New York
$2.84M +$31.5K +1,119 +0.9%
Swiss National Bank
50
Swiss National Bank
Switzerland
$2.4M +$206K +7,300 +8%
1
2
3 4 5

PTGX Hedge Fund Activity: Q1 2022 in Review

140 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q1 2022, worth a combined $1.19B — down 29% from $1.67B a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of PTGX and 20 opened new positions — a net loss of 9 holders — while 47 trimmed existing stakes and 54 added.

The largest buyer was RTW Investments, adding an estimated $61.8M. The largest seller was EcoR1 Capital, cutting an estimated $63.6M.

  • 140 institutional investors held Protagonist Therapeutics (PTGX) as of Q1 2022, down from 149 in Q4 2021.
  • Funds reported $1.19B of Protagonist Therapeutics stock for Q1 2022, down 29% quarter-over-quarter.
  • 20 funds opened new Protagonist Therapeutics positions in Q1 2022 and 29 closed out, a net change of -9 holders.
  • The largest Protagonist Therapeutics buyer in Q1 2022 was RTW Investments, an estimated $61.8M added.
  • The largest Protagonist Therapeutics seller in Q1 2022 was EcoR1 Capital, an estimated $63.6M sold.

Based on aggregated 13F filings for Q1 2022.